Subcutaneous insulin-like growth factor-1 treatment in spinocerebellar ataxias: An open label clinical trial

Movement Disorders

Volumn 26, Issue 2, 2011, Pages 358-359

  Arpa, Javier ^a   Sanz Gallego, Irene ^a   Medina Báez, Josmarlin ^a   Portela, Luis Valmor Cruz ^b   Jardim, Laura Bannach ^b,c   Torres Aleman, Ignacio ^c,d   Saute, Jonas Alex Morales ^b,e  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Univ Fed Do R   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d INSTITUTO CAJAL   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATAXIN 3; ATAXIN 7; CREATININE; GLUCOSE; RECOMBINANT SOMATOMEDIN C;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIET RESTRICTION; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FOLLOW UP; HUMAN; LETTER; NEUROMODULATION; NEUROPROTECTION; OPEN STUDY; OUTCOME ASSESSMENT; PNEUMONIA; PREGNANCY TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPINOCEREBELLAR ATAXIAS 3; SPINOCEREBELLAR ATAXIAS 7; SPINOCEREBELLAR DEGENERATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANALYSIS OF VARIANCE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR I; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SPINOCEREBELLAR ATAXIAS; TREATMENT OUTCOME;

EID: 79952649534     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23423     Document Type: Letter

References (7)

1. Schöls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 2004; 3: 291-304.
2. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004; 3: 169-178.
3. Emamian ES, Kaytor MD, Duvick LA, et al. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 2003; 38: 375-387.
4. Vig PJ, Subramony SH, D'Souza DR, Wei J, Lopez ME. Intranasal administration of IGF-I improves behavior and Purkinje cell pathology in SCA1 mice. Brain Res Bull 2006; 69: 573-579.
5. Yamamoto A, Cremona ML, Rothman JE. Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J Cell Biol 2006; 172: 719-731.
6. Sorenson EJ, Windbank AJ, Mandrekar JN, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008; 71: 1770-1775.
7. Schmitz-Hübsch T, Fimmers R, Rakowicz M, et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 2010: 74; 678-684.